Skip to main content
Premium Trial:

Request an Annual Quote

Athersys, 3DP Enter Pact to Develop, Commercialize Therapeutics

NEW YORK, Oct. 29 — Athersys and 3-Dimensional Pharmaceuticals on Monday announced a collaboration to discover and commercialize novel small-molecule pharmaceuticals for disease treatment. 

Terms of the deal call for Cleveland-based Athersys to use its functional genomics technology to complement 3-Dimensional Pharmaceuticals’ drug-development and optimization experience. 

Athersys will use its RAGE technology to screen compounds, and 3DP, based in Exton, Pa., will identify and optimize those lead compounds. The two companies will jointly choose research targets, the companies said.

The firms have not disclosed the therapeutic areas, but they will be looking at a variety of targets in the G-protein coupled receptor family of proteins, said Kathryn Garvey, director of planning and investor relations at Athersys.

In some cases, the two firms will share development costs and commercialization rights for potential new drug candidates. In other cases, development and commercialization will be conducted independently.

No other financial details of the collaboration were made public.

The deal represents a new kind of venture for Athersys, added Garvey. “It’s nice for Athersys, because we’re building our own pipeline with this collaboration,” she said. “We’ve done some partnerships, and we’ve done some straightforward 50/50 collaborations. This is the first where we have some joint development, and some exclusivity as well,” she said. 

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.